Edition:
India

Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

1.46CAD
18 Oct 2019
Change (% chg)

$-0.02 (-1.35%)
Prev Close
$1.48
Open
$1.54
Day's High
$1.54
Day's Low
$1.33
Volume
118,198
Avg. Vol
163,466
52-wk High
$4.94
52-wk Low
$0.34

Latest Key Developments (Source: Significant Developments)

Resverlogix Announces Pricing Of Unit Offering
Wednesday, 15 May 2019 

May 15 (Reuters) - Resverlogix Corp ::RESVERLOGIX ANNOUNCES PRICING OF UNIT OFFERING.RESVERLOGIX CORP - PRICED ITS PREVIOUSLY ANNOUNCED MARKETED OFFERING OF UNITS OF COMPANY AT $4.00 PER UNIT.RESVERLOGIX CORP - EACH UNIT CONSISTS OF ONE COMMON SHARE AND ONE COMMON SHARE PURCHASE WARRANT.  Full Article

Resverlogix Announces 3-Month Loan Extension
Friday, 3 May 2019 

May 2 (Reuters) - Resverlogix Corp ::RESVERLOGIX ANNOUNCES 3-MONTH LOAN EXTENSION.RESVERLOGIX CORP - ENTERED INTO AN AMENDING AGREEMENT WITH THIRD EYE CAPITAL.RESVERLOGIX CORP - AMENDMENT EXTENDS MATURITY DATE OF COMPANY'S SENIOR SECURED TERM LOAN BY THREE MONTHS TO AUGUST 4.RESVERLOGIX CORP - LENDERS AGREED TO REDUCE MINIMUM CASH BALANCE THAT COMPANY IS REQUIRED TO MAINTAIN FROM US$5 MILLION TO US$3 MILLION.  Full Article

Resverlogix Corp Announces TSX Review Update
Thursday, 12 Apr 2018 

April 12 (Reuters) - Resverlogix Corp ::RESVERLOGIX ANNOUNCES TSX REVIEW UPDATE.DAY EXTENSION TO NO LATER THAN MAY 14, 2018 FOR TSX'S REVIEW OF CO'S COMPLIANCE WITH ALL OF TSX LISTING REQUIREMENTS.  Full Article

Resverlogix Exceeds Full Enrollment For The Pivotal Phase 3 Betonmace Clinical Trial
Monday, 19 Mar 2018 

March 19 (Reuters) - Resverlogix Corp ::RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL.RESVERLOGIX CORP - EXPLORING OPTION OF US ENROLLMENT IN BETONMACE TRIAL AS WELL AS OPTION OF RELYING ON EXISTING BETONMACE DATA TO FILE A US NDA.RESVERLOGIX CORP - ‍ PRIMARY ENDPOINT READ-OUT OF ONGOING PHASE 3 BETONMACE TRIAL AROUND END OF 2018​.  Full Article

Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Resverlogix Corp ::RESVERLOGIX RECEIVES FDA PROTOCOL ACCEPTANCE FOR THE ONGOING PHASE 3 BETONMACE TRIAL.RESVERLOGIX CORP - BETONMACE TOP LINE DATA IS STILL PLANNED TO BE AVAILABLE AROUND END OF 2018.RESVERLOGIX - BETONMACE TRIAL WILL NOW BE EXPANDED TO NORTH AMERICA.  Full Article

Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Resverlogix Corp ::RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT.RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​.RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION.RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO'S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY.RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION.  Full Article

Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for Apabetalone
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Resverlogix Corp :Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for phase 3 study of Apabetalone.Resverlogix - ‍independent DSMB recommended phase 3 study of Apabetalone should continue as planned without modifications ​.Resverlogix Corp - ‍full enrollment for phase 3 study of apabetalone now anticipated in first half of 2018​.  Full Article